Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation
Shanna A. Arnold, Rolf A. Brekken(Southwestern Medical Center)
Cited by 77
Related Papers
Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution
|JCI Insight|2019|281
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
|JCI Insight|2018|111
Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium
|PLoS ONE|2011|99
Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer
|EMBO Molecular Medicine|2019|87
Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution
|bioRxiv (Cold Spring Harbor Laboratory)|2019|75